HematologyAstraZeneca
AstraZeneca Reports Phase 3 Results for Roxadustat in Anemia Associated with MDS
BMI
Biotechnology Media Insights
Editorial Team · August 28, 2025
AstraZeneca announces Phase 3 trial results showing roxadustat effectively treats anemia in patients with lower-risk myelodysplastic syndromes.
AstraZeneca today announced Phase 3 trial results for roxadustat in patients with anemia associated with lower-risk myelodysplastic syndromes (MDS). The trial demonstrated significant increases in hemoglobin levels and reductions in transfusion requirements compared to placebo.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.